Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 billion deal

Published 09/01/2017, 05:56
© Reuters.  France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 billion deal
CSGN
-
SHP
-
IPN
-
MACK
-

(Reuters) - French drugmaker Ipsen SA (PA:IPN) said on Monday it would buy some assets of Merrimack Pharmaceuticals Inc (O:MACK), including pancreatic cancer drug Onivyde, for up to $1 billion, barely a month after the U.S. company stopped a breast cancer drug trial.

The deal would give Merrimack the resources to fund the development of three new compounds targeting pancreatic, lung, and other types of cancers. It would boost Ipsen's portfolio, which has traditionally focused on endocrinology.

Ipsen will pay $575 million at the closing of the deal and up to $450 million more, contingent on some approvals for Onivyde in the United States.

Ipsen would get U.S. commercialization rights for Onivyde and Merrimack's current licensing agreements with Shire Plc (L:SHP) outside the United States and with PharmaEngine Inc for Taiwan.

However, Merrimack said it will retain up to $33 million in milestone payments pursuant to its licensing deal with Shire.

The French company would also buy Merrimack's generic version of ovarian cancer treatment doxorubicin hydrochloride liposome injection, marketed as Doxil, in the United States.

The deal includes Merrimack's commercial and manufacturing assets, Ipsen said.

Merrimack's chief executive resigned in October as it embarked on a restructuring, including job cuts to save costs and focus on research and development.

Merrimack said it plans to return at least $200 million to stockholders through a special cash dividend of about $1.54 per common share. It will also return all of the expected $450 million payment to shareholders.

Upon completion of the deal, Merrimack would have about 80 employees, just a fifth of its strength prior to the restructuring initiated in October.

The deal, to be funded by Ipsen's existing cash and lines of credit, would be dilutive to the drugmaker's earnings in 2017 but will add to earnings from 2018, the company said.

MTS Health Partners LP and Dechert LLP advised Ipsen on the deal. BofA Merrill Lynch and Credit Suisse (SIX:CSGN) Securities (USA) LLC were advisers to Merrimack.

Reuters reported the deal earlier on Sunday, citing people familiar with the matter.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.